RedHill Biopharma (RDHL) Posts Smaller Q1 Loss

RedHill Biopharma (NASDAQ: RDHL) reported Q1 EPS of ($0.03), $0.20 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $24.3 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• T-Mobile (TMUS) Tops Q2 EPS by 27c; offers outlook
• Honeywell Technologies (HON) Tops Q2 EPS by 13c, raises guidance
• Mobileye (MBLY) Tops Q2 EPS by 13c, Beats on Revenue; Offers FY26 Revenue Guidance